Posted by Michael Wonder on 12 Jul 2023
Biosyngen's first in class cell therapy BRG01 receives FDA fast track designation
12 July 2023 - On July 6, 2023, Biosyngen received an official notification from the US FDA granting fast track designation to its revolutionary first in class immunotherapy, BRG01, for the treatment of relapsed/metastatic nasopharyngeal carcinoma.
BRG01, an immunotherapy drug developed by Biosyngen, has received regulatory approvals from both the China National Medical Products Administration on 14 December 2022, and the US FDA on 16 February 2023 respectively; as an investigational new drug for the treatment of relapsed/metastatic nasopharyngeal carcinoma.
